605507.SS · 国邦医药
China A-shares · RS rating 50 · As of 2026-10-14
| Price | 16.25 CNY |
|---|---|
| 1-day change | -1.6% |
| RS rating (overall / 1M / 3M / 12M) | 50 / 89 / 75 / 29 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 23 / 9 / 15 |
| Industry group (rank) | Medical-Generic Drugs (40) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +6.6% |
| Distance from 52-week high | +44.4% |
| Market cap (USD) | $2.0B |